key: cord-0913362-wm8s2qqa
authors: Mnyambwa, Nicholaus P.; Lubinza, Clara; Ngadaya, Esther; Senkoro, Mbazi; Kimaro, Godfather; Kagaruki, Gibson B.; Binagi, Stanley; Malima, Amani; Kazyoba, Paul; Oriyo, Ndekya; Mghamba, Janneth M.; Fredrick, Aman; Ramaiya, Kaushik; Zumla, Alimuddin; Jaffar, Shabbar; Mfinanga, Sayoki G.
title: Clinical characteristics and outcomes of confirmed COVID-19 patients in the early months of the pandemic in Tanzania: A multicentre cohort study
date: 2022-01-06
journal: IJID Regions
DOI: 10.1016/j.ijregi.2021.12.010
sha: 57c15a76ea0150afb25de05a5f78bcf6b14f0cf6
doc_id: 913362
cord_uid: wm8s2qqa

Background We performed a prospective cohort study of the clinical presentations and management outcomes of laboratory-confirmed COVID-19 patients in the early months of the pandemic at two hospitals in Dar es Salaam, Tanzania. Methods Between April 1 - May 31, 2020, laboratory-confirmed COVID-19 patients seen at two tertiary facilities were consecutively enrolled in the study and followed up for 21 days. Results We enrolled 121 COVID-19 patients; 112 (92.6%) were admitted while 9 (7.4%) were seen as outpatients. The median (IQR) age of patients was 41 (30-54) years; 72 (59.5%) were male. The medians (IQR) reported days from hospital admission to recovery and death was 10 (6-18) and 5.5 (3-9), respectively. Forty-four (36.4%) patients had at least one underlying condition. Of the 112 admissions, 17 (15.2%) went to ICU, of which 14 (82.3%) died. At the end of follow-up, 93(76.9%) recovered, and 18 (14.9%) died, 7 (5.8%) remained asymptomatic, and 1 (0.8%) was still ill. Overall, 46 (38.3%) patients had at least one underlying condition. Conclusion Three-quarters of all COVID-19 patients were aged less than 60 years, reflecting Africa's young population structure. High admission rates to ICU and death rates were observed.

Coronavirus Disease 2019 was first reported in Wuhan, China (Phelan et al., 2020) caused by a highly contagious novel coronavirus named Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) (Gorbalenya et al., 2020) The outbreak was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020 , (WHO, 2020d and as of July 17, 2021, more than 189 million cases including at least 4 million death had been reported worldwide (WHO, 2021) . Sub-Saharan Africa, including Tanzania , which has the most vulnerable populations due to the high prevalence of HIV/AIDS, tuberculosis, and malnutrition coupled with a weak health system compared to other continents, had notified only <0.05% of all cases worldwide (WHO, 2021) , augments the need for more scientific evidence to explain the nature of the pandemic.

Although most people infected with SARS-CoV-2 develop only mild/asymptomatic or uncomplicated illnesses, approximately 14% develop a severe disease requiring hospitalization and oxygen support with increased fatality rates (WHO, 2020a) . Individuals infected with SARS-CoV-2 have been reported to exhibit a varying spectrum of clinical features ranging (Cascella et al., 2020; Chen et al., 2020; Huang et al., 2020; Pan et al., 2020; Wang et al., 2020) and that have been changing from mild to more life-threatening as a result of the emerging highly transmissible variants (Guan et al., 2020; Lai et al., 2020; .

People with underlying conditions such as hypertension, chronic lung disease, diabetes, and cardiovascular diseases have compromised immune systems, and are more likely to suffer from severe disease and high fatality rate (CDC COVID-19 Response Team, 2020; WHO, 2020a) . The risk for serious adverse outcomes increases with the number of underlying conditions; those with three or more underlying conditions suffer the most (Ye et al., 2020) . Similarly, findings from Europe and America have shown that COVID-19 infection in individuals over 60 years (Bonanad et al., 2020; WHO, 2020a) , is associated with severe adverse outcomes. The proportion of severe or fatal infections have also been reported to vary by geographical region/location. Here, we present findings on the clinical characteristics and management outcomes of 121 laboratory-confirmed COVID-19 patients in the early months of the pandemic in Tanzania.

This was a prospective follow-up study conducted at two hospitals-Amana Referral and Hindu Mandal Hospital, both located in Dar es Salaam, Tanzania. Amana Referral Hospital is a public hospital, and on April 15, 2020, it was designated COVID-19 Centre and closed to non-COVID-19 patients. Thus, Amana managed COVID-19 cases from across Dar es Salaam city. Hindu

Mandal is a private, not-for-profit hospital that generally sees an older and wealthier population.

COVID-19 cases were identified under the coordination of the National Surveillance System, Ministry of Health, Community Development, Gender, Elderly, and Children (MoHCDGEC).

Only laboratory-confirmed cases were enrolled in the study. Individuals who presented at the hospitals with suggestive symptoms were tested, and those who were confirmed positive were invited to enrol in the study. Patients were consecutively recruited between April 1-May 31, 2020, and followed up for 21 days to monitor clinical outcomes. In cases of death, the cause of death was determined and documented by the certifying physician. The study protocol was approved by the National Health Research Ethics Committee under the National Institute for Medical Research, Tanzania, and written informed consent/assent was obtained from study participants or parents/guardians for minors.

Under the MoHCDGEC, Tanzania, the National Rapid Response Team was responsible for sample collection and transportation for COVID-19 testing. Sample handling was as per the protocol described previously (WHO, 2020c) . Laboratory confirmation of SARS-CoV-2 was done using real-time PCR at the National Public Health Laboratory located in Dar es Salaam, as per the protocol described previously (Guan et al., 2020) . Serum samples were collected from cases as soon as possible after laboratory confirmation. Laboratory tests were performed at Chest X-ray was performed only when requested by the attending physician. Diagnosis of acute respiratory distress syndrome (ARDS) was based on the acuteness of respiratory symptoms, bilateral opacities observed on chest X-ray, and impaired oxygenation as per the WHO guideline on clinical management of severe acute respiratory infection in COVID-19 patients (WHO, 2020b) . Underlying conditions were self-reported by patients based on the previous diagnosis or were reported on referral notes for referred cases.

We collected data on socio-demographic characteristics, symptoms, exposure history, and preexisting medical conditions using standardized data collection forms that were adopted from the World Health Organization (WHO) forms. Attending physicians conducted interviews with patients or their relatives in the case of minors, severely/critically ill, or deceased patients. Blood samples were taken immediately after the patient was diagnosed with COVID-19. Within an hour of collection, samples were transported in cooler boxes spiked with ice packs to the Central Pathology Laboratory at Muhimbili National Hospital for laboratory analysis. Data were managed using Go. Data (https://www.who.int/godata) open-source software.

Bivariate analysis to compare the association between symptoms, pre-existing conditions, and socio-demographic characteristics against mortality rate was conducted. Association between explanatory and response variables was done using Chi-square. The relationship between the explanatory variables (symptoms, age, sex, and comorbidity) against the death rate over a follow-up period of 21 days was analyzed using the Cox regression model. Association was valid if the p-value was less than 5%.

A total of 121 people positive with COVID-19 were recruited. The majority were male and ≤ 60 years old. Seven were children, while 4 were pregnant women (see Table 1 ). Table 2 shows sociodemographic characteristics and presenting symptoms among patients. The majority of patients presented with headache (54.6%), cough (48.8%), fever (47.8%), shortness of breath (46.3%), fatigue (45.5%), and chest pain (41.3%). The median time from onset of symptoms to reporting to the hospitals was 3 (IQR = 1-6) days. Seven (5.8%) patients were asymptomatic 1 ; 1 adult (35 years old female) and six children (aged 3 -12 years). These patients were among individuals who were isolated as a result of an outbreak at the oncology ward at the shortness of breath, altered consciousness, muscle pain, and neurological signs were significantly associated with mortality in COVID-19 patients (Table 2 ). Physical examination revealed that 58 (48%) patients were febrile, 48 (40%) had dyspnea and tachypnea, 18 (14.9%) had abnormalities on lung auscultation, 13 (10.7%) had pharyngeal exudates, 3 (2.5%) had seizure, 1 (0.8%) was in coma and 1 (0.8%) had conjunctival injection.

Above you are combining children and adultse.g. when presenting heart disease or diabetes.

Of the 121 patients, 9 (7.0%) were seen as outpatients, and the remainder 112 (93%) were hospitalized. 17/112 (15.2%) of hospitalized patients were admitted to ICU, and 14 (5 were female) died, which translates to an ICU death rate of 82.4%. Of the 95 patients who were admitted to the medical ward, 4 (4.2%) died. Of all 112 hospitalized patients, 84 (75%) recovered as did for all 9 (100%) outpatients. All 7 (5.8%) asymptomatic patients remained asymptomatic at the end of the follow up. The death rate for all admissions was 16.07% (18/112), and the overall death rate for all COVID-19 patients (including those seen as outpatients) was 14.9% (18/121) ( Figure 1 ). Out of 44 patients with underlying conditions, 12 died (mortality rate = 27.3%). Among the remaining 77 patients without underlying conditions, six died (mortality rate = 8.0%). All children in this cohort survived. The median (IQR) age of patients who died was 58.0 (54-61) years. Median time from onset of symptoms to; hospital admission was 3.0 (1-6), recovery ([14 9-22]), death (10.5 [8-13]) (Table 1) .

A total of 7 patients had complications at the time of recruitment; acute renal failure (2), cardiac failure (2), hypertension requiring vasopressors (2), and 1 had consumptive coagulopathy (Table   3 ). Overall, 46 (38.3%) patients had one or more underlying conditions, 24 (19.8%) had a single underlying condition, 13 (10.7%) had two underlying conditions, while 7 (5.8%) had three or more underlying conditions. The cause of death was determined and documented by the certifying doctor. COVID-19 was the primary cause of death in 3 patients and secondary/contributing for 15 patients. The immediate cause of death for all 18 fatalities was respiratory failure following severe acute respiratory distress syndrome.

Of those who died, 12/18 (66.7%) had at least one comorbidity while 4 had two or more comorbidities; 6 had heart diseases, three diabetes, and 2 HIV. Of the survivors, 32 (31.1%) had at least one comorbidity, 10 (31.3%) heart disease, 7 (21.9%) diabetes, 2 (6.3%) HIV and 7 (21.9%) were obese. Among survivors with comorbidity, 16 (50.0%) had two or more comorbidities. Bivariate analysis showed that heart disease and HIV were significantly associated with mortality in COVID-19 patients (Table 3 ).

In addition, both unadjusted and adjusted analyses showed an association of mortality with comorbidity, shortness of breath, fatigue, muscles pain, altered consciousness, and age (Table 4 and 5). The death rate recorded at 6-week was 0.4 for COVID-19 patients with comorbidity and 0.125 for patients without comorbidity from the date of onset of symptoms. The last death was recorded at week 3 for patients with comorbidity and week 5 for patients without comorbidity (Table 6) .

Chest X-ray was done in 24 patients on admission, and radiographs showed that 8 had bilateral atypical pneumonia, eight bilateral pneumonia, two ground-glass opacities, one bilateral interstitial lung disease, and one unilateral interstitial lung disease. The remaining four patients had a normal chest X-ray.

This study provides insights into the clinical characteristics and outcomes of SARS-CoV-2 infection at the early of the pandemic 2020, first, report in Tanzania. Generally, patients infected with SARS-Cov-2 presented with symptoms similar to those described previously (Cascella et al., 2020; Chen et al., 2020; Guan et al., 2020; Huang et al., 2020; Lai et al., 2020; Pan et al., 2020; Wang et al., 2020; ; and three-quarters were aged ≤60 years), high comorbidities, hospital mortality, and admission to ICU were observed. Quantitative D-dimer levels were elevated in three-fifths and decreased PTT (3/5), and PT (3/10) were observed. These indicators suggest the existence of the thromboembolic process, which includes disseminated intravascular coagulation, pathogenesis that is consistent with COVID-19.

Males constituted most of the COVID-19 patients, and these findings are constituent with prior studies in COVID-19 patients (Goyal et al., 2020; Grasselli et al., 2020; Guan et al., 2020) and

other respiratory infectious diseases. The median age of the participants was 41 years, equivalent to that reported in South Africa (Kaswa et al., 2021) , relatively lower than those reported in China (47 years) (Guan et al., 2020) , Libya (56) (Elhadi et al., 2021) , New York (62.2 years) (Goyal et al., 2020) , and Italy (63) (Grasselli et al., 2020) . Also, the majority of COVID-19 patients were aged ≤ 60 years, which reflects the demographic structure of sub-Saharan Africa that is dominated by a younger population as compared to other regions of the world. The young population can be considered as a protective factor against the disease severity. Our findings reported a case fatality rate of 15% that was relatively higher than those reported in Europe and America. Guan et al., 2020; Huang et al., 2020) However, the hospital death rate was lower (16.1%) compared to that reported in Europe (22.9%) and America (22.23%) (Goel et al., 2020) . In the present study, the admission rate to ICU was 14% and previous studies have reported that rates for patients requiring admission to ICU range from 5% to 26% (Immovilli et al., 2020; Richardson et al., 2020; Wang et al., 2020; WHO, 2020a; . In this study, the mortality rate among those admitted to ICU was high at 82%, which corroborates with those described in the previous studies (Auld et al., 2020; Bhatraju et al., 2020) . Previous studies have demonstrated that individuals aged over 60 years and those with underlying conditions are at the highest risk for severe disease and poor clinical outcomes, including high mortality (CDC COVID-19 Response Team, 2020; WHO, 2020a).

Our findings suggest that clinical manifestations of COVID-19 that range from asymptomatic, mild to acute respiratory failure and even death were consistent with those published previously (Cascella et al., 2020; Chen et al., 2020; Guan et al., 2020; Huang et al., 2020; Lai et al., 2020; Pan et al., 2020; Wang et al., 2020; . ARDS is the common clinical manifestation of severe COVID-19; 17% of patients developed ARDS in this cohort. Abnormal chest radiograph was observed in 20/24 patients, of which 16 had chest X-ray radiograph suggestive of pneumonia. Variation in proportions of symptoms and disease severity in this study can be attributed to geographical factors and/or merely by chance. For example, in our study, the headache was the most common complaint among COVID-19 patients, while in China and New York, the cough was the most presenting symptom reported (Auld et al., 2020; Guan et al., 2020) in COVID-19 patients. Children represented a small portion of the participants (5.8, N=7), of which six children did not develop symptoms and remained asymptomatic for 21 days of followup. This observation is consistent with previous studies which have reported a high prevalence of asymptomatic and mild COVID-19 cases among children (Arons et al., 2020; Miri et al., 2020) .

The presence of a large percentage of mild and asymptomatic cases may imply that many cases are going unnoticed, especially in sub-Saharan Africa, where poor health-seeking behaviour is common, and this might be contributing to the virus spread; thus, a call for rigorously case finding to halt the transmission.

Our basic analysis focusing on renal and liver function and hematological parameters demonstrated inflammatory markers were elevated in most COVID-19 patients suggesting the presence of damage in these vital organs. Previous studies have reported COVID-19 to affect nearly all of the body's primary organs and cause damage (Auld et al., 2020; Chen et al., 2020; Tang et al., 2020) .

In conclusion, we have presented the first report on clinical characteristics and outcomes in patients infected with COVID-19 in the Tanzanian context. The majority of COVID-19 patients were aged ≤60 with a high proportion of comorbidities. The mortality rate reported in this study is comparable to other hospital-based studies, and the ARDS was the main cause of death. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Infections (PANDORA-ID-NEThttps://www.pandora-id.net/) and EXIT-TB project, both funded by the European and Developing Countries Clinical Trials Partnership (EDCTP). 

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Features, Evaluation and Treatment Coronavirus (COVID-19)

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Epidemiological and clinical presentations of hospitalized COVID-19 patients in Libya: An initial report from Africa

Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe

The species and its viruses -a statement of the Coronavirus Study Group

Clinical Characteristics of Covid-19 in

Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2

Admitted to ICUs of the Lombardy Region, Italy

Clinical characteristics of coronavirus disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

COVID-19 mortality and ICU admission: The Italian experience

Clinical outcomes of hospitalised COVID-19 patients at Mthatha Regional Hospital

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

Tanzania's position on the COVID-19 pandemic

Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues

Knowledge, awareness and use of HIV services among the youth from nomadic and agricultural communities in Tanzania

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical Characteristics of

Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected

Laboratory testing for the 2019 novel Corona virus (2019-nCoV) in suspected human cases

WHO Timeline -COVID-19

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus

Dashboard With Vaccination Data

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a

Cases From the Chinese Center for Disease Control and Prevention

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang

The authors thank the Ministry of Health, Community Development, Gender, Elderly, and Children and Clinicians and the administration of the two hospitals for their support in the coordination and implementation of this study. Nicholaus Mnyambwa, Mbazi Senkoro, Gibson Kagaruki, and Sayoki Mfinanga received partial support from the Afrique-ONE Aspire (funded by Wellcome Trust) while conducting this research and preparing the manuscript.